Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

What dosage were you prescribed daily?

Did side effects from Mobic include any of the following?

Date the medical problem(s) first occurred:

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Mobic Side Effects Lawsuits: | Side Effects: Heart Attacks, Heart Problems, Highest Risk of Heart Attack

Mobic Side Effects Could Lead To Heart Attack Lawsuits

Mobic | Lawsuits, Lawyers | Side Effects: Heart Attacks, Increased Risk Of Heart Problems

Mobic (Generic: Meloxicam) carries a greater risk of heart attacks in early data than found with Merck & Co.'s Vioxx, a veteran U.S. Food and Drug Administration scientist told an FDA advisory panel. The drug, manufactured by Boehringer Ingelheim Pharmaceuticals, exhibited the effect in a new study that has yet to be published, said David Graham, associate director for science and medicine at the FDA's Office of Drug Safety.

We found an increased risk, Graham said. It's one study. It's the only study. Mobic has become the top-selling prescription pain drug since Merck pulled Vioxx in September 2004, and any possible heart attack risk is important as more patients take the drug, Graham said. Graham, along with other scientists outside the FDA, analyzed data from California's Medicaid program of more than 15,000 heart attack patients, making it the largest study to date on such risks. They found the statistical risk of heart attack was 1.37 for Mobic, compared to 1.32 with Vioxx and 1.09 with Celebrex.

Celebrex, Bextra and Vioxx, are part of a class called Cox-2 inhibitors, a newer type of non-steroidal anti-inflammatory drug (NSAID). Mobic is classified as a Cox-2 in some countries but is not considered part of that group in the United States, where it's only classified as part of the larger NSAID class. Abbott Laboratories, which co-markets Mobic in the United States, said it expects U.S. sales of the drug to hit $1 billion in 2005.

Legal Help For Victims Affected By Mobic

If you or a loved one took Mobic and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


Caution Urged On Alternative Painkillers

As patients have turned to other painkillers to avoid the cardiovascular risks associated with Vioxx, Bextra and Celebrex, scientists are casting suspicion on several of the substitutes, especially Mobic.Prescriptions for Mobic have tripled since September, when the maker of Vioxx voluntarily withdrew the COX-2-inhibiting painkiller because of findings of heart problems. Immediately, the maker of Mobic began courting former Vioxx users, through ads and company representatives' visits to...

Fresh Warning Issued For Painkillers

Feb 22, 2005 | TVNZ, New Zealand
Health officials have signalled that a popular group of painkillers may be taken off the market because of the increased risk of heart attack and stroke.After reviewing the cardiovascular safety of the Cox-2 inhibitors, Celebrex, Arcoxia, Mobic, Bextra and Dynastat, Ministry of Health officials have concluded the risk of heart attack and stroke outweighs the benefits of the drugs.People who are at high risk of "cardiovascular events" should see their doctor and switch to a different medication,...

Vioxx Alternative Risky, Official Says

Feb 18, 2005 | Washington Post
David Graham, a veteran Food and Drug Administration safety officer and recent whistleblower, on Thursday told a conference reviewing the risks of arthritis painkillers that Mobic, the medication that hundreds of thousands turned to after Vioxx and other COX-2 inhibitors came under a cloud, is potentially just as dangerous.Graham said a large new study he and a colleague had just completed, which FDA officials initially did not want him to present because it was preliminary, indicates that the...

FDA Scientist Sees Problems With Entire Class Of Painkillers

Feb 18, 2005 | Baltimore Sun
Food and Drug Administration whistle-blower David J. Graham told a panel of scientists yesterday that he believed high doses of the Cox-2 inhibitor drug Celebrex pose a risk of increased heart attack or stroke but the risk drops at lower doses.Graham, testifying on his findings on the safety of several painkillers widely used by arthritis patients, also raised the possibility of cardiovascular risk in taking Mobic, or meloxicam. The top-selling drug is from a more traditional class of...

More Mobic News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo